PMID- 28361451
OWN - NLM
STAT- MEDLINE
DCOM- 20180313
LR  - 20181202
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Linking)
VI  - 12
IP  - 3
DP  - 2017 Jun
TI  - Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell 
      Carcinoma.
PG  - 333-340
LID - 10.1007/s11523-017-0487-4 [doi]
AB  - OBJECTIVE: We conducted a retrospective analysis of two clinical trials in 
      treatment-naive patients (n = 402) with advanced renal cell carcinoma (RCC) 
      treated with axitinib. Our objective was to compare duration of treatment (DT) 
      and clinical outcome in patients who achieved DT >18 months (longer DT) versus 
      </=18 months (shorter DT). PATIENTS AND METHODS: DT, objective response rate (ORR), 
      tumor shrinkage, and overall survival (OS) were summarized for patients with 
      longer and shorter DT. RESULTS: Overall, 152 patients (37.8%) had longer DT and 
      250 (62.2%) had shorter DT (median, 34.7 vs. 6.5 months, respectively). ORR in 
      all 402 patients with advanced RCC was 43.5%. ORR was 75% for longer DT versus 
      24.4% for shorter DT (p < 0.0001). More patients with longer DT versus shorter DT 
      had >/=10% tumor shrinkage at first scan (74.8% vs. 55.3%; p = 0.0001) and maximum 
      on-study tumor shrinkage was greater in longer-DT versus shorter-DT group (-51.8% 
      vs. -22.1%; p < 0.0001). Median OS was 32.6 months in the overall population 
      while in the patients with longer DT the median was not reached. 
      Treatment-related adverse events (AEs) grade >/=3 were more frequent in longer-DT 
      versus shorter-DT and included hypertension (25.7% vs. 18.8%), diarrhea (15.1% 
      vs. 4.4%), and weight decrease (11.2% vs. 3.2%); however, these AEs decreased 
      over time in both groups. Eastern Cooperative Oncology Group performance status 
      0, favorable hematology values, no bone or liver metastases, and baseline tumor 
      burden below the overall median were associated with longer DT. CONCLUSIONS: 
      Longer duration (>18 months) of axitinib treatment was associated with increased 
      frequency of early tumor shrinkage, greater magnitude of tumor shrinkage, and a 
      favorable OS.
FAU - Rini, Brian I
AU  - Rini BI
AD  - Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, 
      9500 Euclid Ave., Desk R35, Cleveland, OH, 44195, USA. rinib2@ccf.org.
FAU - Gruenwald, Victor
AU  - Gruenwald V
AD  - Hannover Medical School, Hannover, Germany.
FAU - Jonasch, Eric
AU  - Jonasch E
AD  - Department of Genitourinary Oncology, Division of Cancer Medicine, The University 
      of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
FAU - Fishman, Mayer N
AU  - Fishman MN
AD  - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
FAU - Tomita, Yoshihiko
AU  - Tomita Y
AD  - Niigata University Graduate School of Medical and Dental Sciences, Niigata, 
      Japan.
FAU - Michaelson, M Dror
AU  - Michaelson MD
AD  - Massachusetts General Hospital Cancer Center, Boston, MA, USA.
FAU - Tarazi, Jamal
AU  - Tarazi J
AD  - Pfizer Oncology, La Jolla, CA, USA.
FAU - Cisar, Laura
AU  - Cisar L
AD  - Pfizer Oncology, Pfizer Inc, New York, NY, USA.
FAU - Hariharan, Subramanian
AU  - Hariharan S
AD  - Pfizer Oncology, Pfizer Inc, New York, NY, USA.
FAU - Bair, Angel H
AU  - Bair AH
AD  - Pfizer Oncology, La Jolla, CA, USA.
FAU - Rosbrook, Brad
AU  - Rosbrook B
AD  - Pfizer Oncology, La Jolla, CA, USA.
FAU - Hutson, Thomas E
AU  - Hutson TE
AD  - Baylor-Sammons Cancer Center, Genitourinary Oncology Program, Dallas, TX, USA.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Imidazoles)
RN  - 0 (Indazoles)
RN  - C9LVQ0YUXG (Axitinib)
RN  - EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor beta)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Axitinib
MH  - Carcinoma, Renal Cell/*drug therapy/mortality/pathology
MH  - Female
MH  - Humans
MH  - Imidazoles/pharmacology/*therapeutic use
MH  - Indazoles/pharmacology/*therapeutic use
MH  - Kidney Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors
MH  - Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Tumor Burden
MH  - Young Adult
EDAT- 2017/04/01 06:00
MHDA- 2018/03/14 06:00
CRDT- 2017/04/01 06:00
PHST- 2017/04/01 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
PHST- 2017/04/01 06:00 [entrez]
AID - 10.1007/s11523-017-0487-4 [pii]
AID - 10.1007/s11523-017-0487-4 [doi]
PST - ppublish
SO  - Target Oncol. 2017 Jun;12(3):333-340. doi: 10.1007/s11523-017-0487-4.